Brookings, a non-profit public policy organization in Washington D.C., has a new report that calls for the federal government to stop impeding medical cannabis research.
“Specifically, the U.S. government has held back the medical community’s ability to conduct the type of research that the scientific community considers the experimental gold standard in guiding medical practice. Thus, the use of cannabis for medical treatment is happening in states based largely on anecdotal or limited science,” authors John Hudak and Grace Wallack said in an introduction to the paper on the Brookings site.
The paper calls on the government to recognize the public policy risks associated with limited research abilities due to the marijuana’s federal status as a Schedule 1 drug with no medical benefits.
“As medical marijuana becomes increasingly accessible in state-regulated, legal markets, and as others self-medicate in jurisdictions that do not allow the medical use of cannabis, it is increasingly important that the scientific community conduct research on this substance. However, statutory, regulatory, bureaucratic, and cultural barriers have paralyzed science and threatened the integrity of research freedom in this area,” authors wrote on the site.
You can read the full report here: Ending the US governments war on medical marijuana research